Plans are in the works to develop a new tool that can detect breast cancer earlier than is currently possible. The University of North Dakota and Neomatrix, LLC, have signed an exclusive agreement to develop the new technology using the HALO® Breast Pap Test device.
Similar to the Pap test for cervical cancer, the HALO® test may detect breast cancer early via abnormal cells in breast nipple aspirate fluid (NAF). Researchers at University of North Dakota identified a promising panel of biomarkers in the NAF. The new partnership aims to help validate this panel and develop an assay. If this research comes to fruition, they will seek FDA approval. The HALO Breast Pap Test is already approved by the FDA.
To learn more about the test, visit neomatrix.com.
Source:University of North Dakota Faculty/Staff Newsletter